Pluma, Andrea http://orcid.org/0000-0003-2541-5766
Micu, Mihaela C.
Julià, Antonio http://orcid.org/0000-0001-6064-3620
Marsal, Sara http://orcid.org/0000-0001-5515-3854
Förger, Frauke http://orcid.org/0000-0003-1134-993X
Østensen, Monika http://orcid.org/0000-0002-3211-1974
Funding for this research was provided by:
Catalan Rheumatic League
Article History
Received: 21 March 2020
Accepted: 4 May 2020
First Online: 18 May 2020
Compliance with ethical standards
:
: Dr. Pluma Sanjurjo reports received the First Research Prize for the social impact of Rheumatic Diseases from Catalan Rheumatic League. Dr. Micu has nothing to disclose. Dr. Julià has nothing to disclose. Dr. Marsal has nothing to disclose. Dr. Förger has nothing to disclose. Dr. Østensen reports during the last 36 months speaker fees from Novartis, Roche, New Bridge, and UCB. She has been consultant for advisory board for Pfizer and for Galapagos pharmaceutical company.
: The Ethics Committee of Rehabilitation Clinical Hospital, Cluj-Napoca, approved the study protocol (Nr. 6422/Date 12.02.2015). The procedures used in this study adhere to the tenets of the Declaration of Helsinki. The ethics committee officer in Bern, Switzerland and in Barcelona, Spain reviewed the project protocol and questionnaire and confirmed that ethical committee approval was not required for this study conducted anonymously and without access to patient identification. Their consent was initially given verbally, but they provided a written confirmation of their decision on our request before submission of the manuscript. The Ethics Committee of Vall d’Hebron University Hospital approved the study (Acta. 345/Date 27.06.2018). The Ethics Committee of University Hospital Inselspital, Bern approved the study (Req-2019-00143/Date 19.02.2019).
: Verbal informed consent was obtained prior to completing the questionnaire.